The Shift in Global Drug Development

The episode begins by setting the stage for the U.S. no longer being the leader in biomedical innovation.

A key point is made that China's advancement in drug development is due to systemic changes in regulatory design and trial structures.

The guest, Kremio, is introduced, with a discussion about his expertise in genetics, psychometrics, and econometrics.

The historical context is established, noting the U.S.'s decades-long dominance in biopharmaceuticals and drug production.

It's stated that China has been the leader in biopharmaceuticals and new drug production since 2016, surpassing the U.S.

The conversation clarifies that this leadership extends to interventions moving through clinical trials and gaining approval.

The dual nature of China's innovation is discussed: it's good for increased access to medicines but raises concerns about potential supply control.

The state's control over corporations in China is highlighted, with examples of government intervention to reorient supply chains.

The strategic importance of leading in cutting-edge medical research is presented as a key meta-story.

The basic structure of clinical trials (Phases 1-4) is explained as a foundation for understanding the subsequent data.

Data is presented showing the U.S. conducts many clinical trials, but China's volume has surged significantly since reforms.

A high failure rate (over 90%) for interventions entering clinical trials is noted, with common reasons being lack of safety or efficacy.

China's progress in clinical trials is contrasted with the U.S., showing a rapid increase in trial volume since their 2016 reforms.

While the combined U.S. and EU are still ahead of China in total trials, China's upward trajectory is steeper.

The trend is shown to translate into new drug approvals originating in China, indicating genuine innovation.

The concept of "me-too" drugs is discussed, where companies copy successful innovations, and China's role in this is explored.

China is noted for its significant activity in novel gene therapy trials, surpassing the U.S. in initiating phase one trials for new gene therapies.

China's advantage in gene therapies is partly attributed to fewer restrictions on germline editing compared to the U.S.

China is also leading in antibody-based and small molecule drug trials, and overall novel drug compounds.

China's trials are less prone to statistical failure due to larger enrollments and more efficient patient recruitment.

A detailed explanation of China's pre-2016 regulatory hurdles is provided, highlighting long review times and the inability to use foreign data.

China's reforms post-2016 are detailed, including accepting overseas data and streamlining review processes.

The approval of parallel ethics committees in China is highlighted as a key efficiency measure not present in the U.S.

China's reforms are framed as abundance-oriented and efficiently implemented, contrasting with the U.S. system.

The Market Authorization Holder (MAH) system in China is praised for streamlining the drug approval process by centralizing responsibility.

China has shortened review times significantly, aiming for much faster approval processes than historically seen.

The impact of long regulatory delays on pharmaceutical company capital and viability is discussed, with U.S. regulations potentially hindering competition.

China's adoption of novel trial design methods, such as innovative control arms, is presented as a key advantage.

China's aggressive approach to eliminating corruption and streamlining processes is noted as a significant factor in its progress.

The discussion shifts to the U.S.'s potential to catch up, with the importance of deregulation and addressing funding issues being raised.

The U.S.'s historical advantage in drug purchasing power and its impact on innovation is discussed, though this advantage is being challenged.

China's negotiation strategy, which lowers drug prices while increasing sales volume and company profits, is highlighted as a remarkably effective model.

The overall positive outcomes of China's approach are summarized: lower prices, increased volume, higher company profits, and improved public health.

The question of how the U.S. can catch up is posed, with the answer pointing to studying and replicating China's reforms.

The challenge of Most Favored Nation (MFN) pricing and its negative impact on U.S. pharmaceutical profits and investment is discussed.

Regulator inconsistency and unpredictable approval processes in the U.S. are identified as major drawbacks.

The potential for the U.S. to lead in AI-driven drug discovery while relying on China for clinical trials is raised as a possible future scenario.

A specific drug, NA931, is discussed, with its potential for significant weight loss and improved tolerability being noted, though with some skepticism.